CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Public ClinicalTrials.gov record NCT03253575. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug combinations) indicated for the stage and type of cancer for treatment. CANscript™ tests how a patients specific tumor reacts to the therapies being considered by the treating physician. CANscript™ test results have been shown to closely correspond with actual clinical results, providing physicians with information that may help him/her develop a more personalized cancer treatment and care plan based on the patients specific condition. The researchers want to see if CANscript™ test results are helpful in selecting the treatments prescribed and provided. There will be about 800 people taking part in this study, across 5 different tumor types. The study is designed to assess the decision impact of the CANscript™ test results in informing physicians in therapy selection.
Study identification
- NCT ID
- NCT03253575
- Recruitment status
- Suspended
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 800 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2017 (Actual)
- Primary completion
- Jul 31, 2019 (Estimated)
- Completion
- Dec 15, 2019 (Estimated)
- Last update posted
- Apr 8, 2019
2017 – 2019
United States locations
- U.S. sites
- 30
- U.S. states
- 14
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| University of Colorado School of Medicine-Denver | Aurora | Colorado | 80045 | — |
| Eastern CT Hematology and Oncology Associates | Norwich | Connecticut | 06360 | — |
| Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Broward Oncology Associates | Fort Lauderdale | Florida | 33308 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| University of Miami-Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| The Center for Gyencologic Oncology | Miramar | Florida | 33027 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Tallahassee Memorial Cancer Center | Tallahassee | Florida | 32308 | — |
| Memorial Health University Medical Center- Savannah Health Services | Savannah | Georgia | 31404 | — |
| Joliet Oncology Associates | Joliet | Illinois | 60435 | — |
| Edward Elmhurst Healthcare | Naperville | Illinois | 60540 | — |
| Community Hospital | Munster | Indiana | 46321 | — |
| Ochsner Health System | New Orleans | Louisiana | 70121 | — |
| Southcoast Centers for Cancer Care | Fairhaven | Massachusetts | 02719 | — |
| Michigan Center of Medical Research -MHP | Farmington Hills | Michigan | 48334 | — |
| St John Hospital and Medical Center (Great Lakes Cancer Managment Specialists) | Grosse Pointe Woods | Michigan | 48236 | — |
| War Memorial Hematology/Oncology | Sault Ste. Marie | Michigan | 49783 | — |
| Mercy Hospital | St Louis | Missouri | 63141 | — |
| University of Rochester/Wilmot Cancer Institute | Rochester | New York | 14642 | — |
| Saint Thomas Health | Nashville | Tennessee | 37205 | — |
| Austin Cancer Centers | Austin | Texas | 78758 | — |
| Doctors Hospital at Renaissance-DHR Health | Edinburg | Texas | 78539 | — |
| University of Texas Medical Branch at Galveston(UTMB) | Galveston | Texas | 77550 | — |
| Oncology Consultants | Houston | Texas | 77024 | — |
| Baylor College of Medicine Hemtology/Oncology | Houston | Texas | 77030 | — |
| Houston Methodist Medical Center | Houston | Texas | 77030 | — |
| The University of Texas Health Science Center at Houston- Hermann | Houston | Texas | 77030 | — |
| Invesclinic US McAllen Oncology | McAllen | Texas | 78577 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03253575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2019 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03253575 live on ClinicalTrials.gov.